A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...
Investor's Business Daily on MSN
Pfizer targets monthly obesity shot. Why Lilly could still have the weight-loss heavyweight.
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results